BNGO

BNGO

USD

Bionano Genomics Inc. Common Stock

$3.700+0.030 (0.817%)

实时价格

Healthcare
Medical Instruments & Supplies
美国

价格图表

Loading Chart...

关键指标

市场指标
公司基本面
交易统计

市场指标

开盘价

$3.670

最高价

$3.780

最低价

$3.660

成交量

0.05M

公司基本面

市值

12.4M

所属行业

Medical Instruments & Supplies

国家/地区

United States

交易统计

平均成交量

0.14M

交易所

NCM

货币

USD

52周价格范围

最低价 $2.68当前价 $3.700最高价 $52.2

相关新闻

Analyst Upgrades

Maxim Group Upgrades Bionano Genomics to Buy, Announces $8 Price Target

Maxim Group analyst Jason McCarthy upgrades Bionano Genomics from Hold to Buy and announces $8 price target.

查看更多
Maxim Group Upgrades Bionano Genomics to Buy, Announces $8 Price Target
GlobeNewswire

Bionano Reports First Quarter 2025 Results and Highlights Recent Business Progress

SAN DIEGO, May 14, 2025 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (NASDAQ:BNGO) today reported financial results for the first quarter ended March 31, 2025. "The first quarter of 2025 represents the first full

查看更多
Bionano Reports First Quarter 2025 Results and Highlights Recent Business Progress
GlobeNewswire

Bionano to Report First Quarter 2025 Financial Results and Host a Conference Call Webcast on May 14, 2025

SAN DIEGO, May 07, 2025 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (NASDAQ:BNGO) today announced that it will host a conference call and live webcast on Wednesday, May 14, 2025, at 4:30 p.m. Eastern Time to report

查看更多
Bionano to Report First Quarter 2025 Financial Results and Host a Conference Call Webcast on May 14, 2025
GlobeNewswire

International Consortium for Optical Genome Mapping Publishes Expert Recommendations for Integration of OGM as a Standard-of-Care Cytogenetic Assay for Diagnostic Workflows in Blood Cancers

SAN DIEGO, May 02, 2025 (GLOBE NEWSWIRE) -- Bionano Laboratories, a wholly-owned subsidiary of Bionano Genomics, Inc. (NASDAQ:BNGO) that offers CLIA-certified laboratory developed tests (LDTs) based on optical genome

查看更多
International Consortium for Optical Genome Mapping Publishes Expert Recommendations for Integration of OGM as a Standard-of-Care Cytogenetic Assay for Diagnostic Workflows in Blood Cancers